Provided by Tiger Trade Technology Pte. Ltd.

B&K CORP-B

5.045
-0.220-4.18%
Volume:53.40K
Turnover:281.52K
Market Cap:593.58M
PE:-2.43
High:5.390
Open:5.250
Low:5.045
Close:5.265
52wk High:37.200
52wk Low:3.500
Shares:117.66M
HK Float Shares:83.02M
Volume Ratio:0.66
T/O Rate:0.06%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-2.080
ROE:-53.92%
ROA:-29.66%
PB:0.91
PE(LYR):-2.43
PS:974.76

Loading ...

B&K Corp sets 4 Sept EGM to seek approval for full H-share circulation, new 10-year share award scheme and interim dividend plan

Bulletin Express
·
Aug 20

B&K Corporation Schedules 4 Sept 2026 EGM to Vote on Full-Circulation, Interim Dividend and Share Award Scheme

Bulletin Express
·
Aug 20

B&K Corp Announces Extraordinary General Meeting

Reuters
·
Aug 20

B&K Corp Proposes Full Circulation of 21.68 Million Domestic Shares; Extraordinary Meeting Set for 4 September 2026

Bulletin Express
·
Aug 14

B&K unveils 10-year Share Award Scheme; first batch of 2.33 million shares earmarked for an employee and a consultant

Bulletin Express
·
Aug 14

B&K CORP-B (02396) Seeks Full Circulation of H Shares

Stock News
·
Aug 14

B&K Corp Proposes Bylaw Changes to Streamline Unlisted-Share Conversion into Hong Kong-Traded H Shares

Reuters
·
Aug 14

B\u0026K CORP-B (02396) Reports 40.65% Wider Net Loss of 122 Million Yuan in Interim Results

Stock News
·
Aug 14

B&K CORP-B 1H26 Net Loss Expands 40.6% to RMB121.92 Million amid Heavier R&D Outlay

Bulletin Express
·
Aug 14

B&K Corp H1 FY26 Loss Widens 40.6% to RMB 121.92 Million

Reuters
·
Aug 14

B&K Corp Schedules 14 August 2026 Board Meeting to Approve 1H26 Results and Consider Interim Dividend

Bulletin Express
·
Aug 04

B&K Corp Sets Board Meeting to Weigh Interim Results, Possible Dividend

Reuters
·
Aug 04

B&K Reports Stable Share Capital and Full Public Float Compliance in July 2026 Update

Bulletin Express
·
Aug 03

B&K Announces Chinese Name Change to 青城新藥生物科技(青島)股份有限公司; Chinese Stock Short Name Shifts to「青城新藥-B」on 22 July 2026

Bulletin Express
·
Jul 17

B&K CORP-B Announces Formal Name Change to Qingcheng New Drug Biotechnology

Stock News
·
Jul 17

B&K: Completes Full Enrollment for Phase II Trial of Diabetic Foot Ulcer Therapy Pro-101-2

Bulletin Express
·
Jul 13

B&K Completes Phase II Trial Enrollment for Pro-101-2 Diabetic Foot Ulcer Treatment

Reuters
·
Jul 13

B&K Corp-B Reports Stable Share Capital with 100% Compliance on Public Float in June 2026 Filing

Bulletin Express
·
Jul 03

Companies Like B&K (HKG:2396) Are In A Position To Invest In Growth

Simply Wall St.
·
Jun 30

B&K Corp shareholders approve share issue mandate at AGM

Reuters
·
Jun 22